Similarly, UMCD6-treated CD8+ lymphocytes, isolated from PBMCs by negative selection, showed greater cancer cell killing with UMCD6 compared with pembrolizumab or nivolumab (Figure 5, C and D). The gene discussed is CD8A; the disease is cancer.